学会発表など
村田達教. 神経因性膀胱による排尿障害を有する患者における間欠導尿用カテーテルの選好と支払意思額に関する離散選択実験法による調査. ISPOR日本部会 第11回学術集会. 2015年8月30日.
Ikeda S, Inoue S, Kobayashi M. Cost-effectiveness analysis of condoliase in patients with lumber disc herniation in Japan. ISPOR 20th Annual International Meeting, May 16-20, 2015, Philadelphia, PA, USA.
Sugimoto T, Kamae I, Yamabe K, Kobayashi M. Assessing the quality of health economic evaluations published in a Japanese setting: a systematic review of the literature for 1991-2012. ISPOR 20th Annual International Meeting, May 16-20, 2015, Philadelphia, PA, USA.
McEwan P, Ward T, Yuan Y, Kalsekar A, Kamae I, Kobayashi M, Inoue S, Tang A, Kumada H. Estimating projected costs and quality-adjusted life expectancy associated with Daclatasvir plus Asunaprevir in difficult to treat Japanese patients chronically infected with HCV Genotype 1b. The annual AASLD liver meeting, 7-11 November, 2014, Boston, MA, USA.
Sugiyama N, Murata T, Morishima Y, Fukuma Y, Shibasaki Y, Marshall L. Treatment pattern and direct cost of biologics for rheumatoid arthritis patients: a real-world analysis of nationwide Japanese claims data. ACR2014, 13-18 November, 2014, Boston, MA, USA.
Sugiyama N, Murata T, Morishima Y, Fukuma Y, Shibasaki Y, Bidad C, Harnett J, Marshall L, Coindreau J. Const-effectiveness of biologics for rheumatoid arthritis patients: a real-world analysis of nationwide Japanese claims data. EULAR , 11-14 June, 2014, Paris, France.
Murata T, Hanada K, Shibahara H. Claims database analysis of patients with chronic hepatitis C in Japan. 17th ISPOR Annual European Congress, 10th November 2014, Amsterdam, The Netherlands.
Kamae I, Ward T, Webster S, Kobayashi M, McEwan P, Kalsekar A, Yuan Y, Inoue S, Tang A, Kumada H. Investigating treatment strategies to optimize clinical outcomes associated with emerging therapies for HCV. APASL, Asian Pacific Association for The Study of the Liver, 12-15 March, 2014, Brisbane, Australia.
Kamae I, Ward T, Webster S, Kobayashi M, McEwan P, Yuan Y, Kalsekar A, Inoue S, Tang A, Kumada H. Estimating the long-term clinical and economic outcomes of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b virus. APASL, Asian Pacific Association for The Study of the Liver, 12-15 March, 2014, Brisbane, Australia.
Shibahara H, Shiroiwa T, Tange C, Nakamura K, Ozono S, Shimozuma K. Reanalysis of cost-effectiveness of abiraterone acetate as second line treatment for metastatic castration-resistant prostate cancer in Japan using a Japanese claim data set. 19th ISPOR Annual International Meeting, 2nd June, 2014, Montreal, QC, Canada.
